China Medipharm Insights - April 2000


Regular Price: USD 1,000.00

Special Price USD 700.00

30% OFF

* Required Fields

Regular Price: USD 1,000.00

Special Price USD 700.00


Be the first to review this product

Table of Contents

China Medipharm Insights - April 2000, China Medipharm InsightsDrug Consumption in ChinaAnalysis Of Prostatic Hyperplasia Drug MarketProduct NewsRh-EGF Launched By Shenzhen HuashengyuanNew Anti-Hepatitis Drug To Be LaunchedLive Chicken-Pox Vaccine To Be MarketedClass II New Drug Rh-GH MarketedTwo Vaccines Of Lanzhou Institute Received NDCTargeted PDP Paclitaxel To Be Produced In SichuanLuofaxin To Be MarketedNerve Growth Factor Commercialized In HeilongjiangQuinapril Marketed By Harbin PharmaDNA Chip Into Trial ProductionAtorvastatin and Famciclovir Launched By Honghui MedicineNew Anti-Obesity TCM MarketedEarly Cancer Detection Reagent LaunchedEstrogen Protects Cerebral Neurons & Cardiovascular SystemFructose Diphosphate Oral Liquid LaunchedDiscarded Placental Amnionic Membrane Effective For Burn HealingFolate Supplements Effective For Newborn DefectsProduct AnalysisDomestic Vitamin C Manufacturers Changing Focus To Home MarketCefradine Market AnalysisCompany ProfilesForeign-Funded Drug Retail Stores To Be Operated In ShanghaiSino-French TCM Joint Venture To Be Established In TianjinTonghua Dongbao Targets International Insulin MarketShanghai Ajinomoto Amino Acid EstablishedRoche Provides Fund for Venereal Disease Control In ChinaHarbin No.3 Pharma Reported 192 Percent Increase In Sales - Led By Gluconate Calcium Guangzhou Pharma Corp Experienced Rapid GrowthShenyang Sunshine Leads Genetic Engineering Sector In China999 Group Targets Entering World Top 500 By 2015WPU Biotech Grows With Its Xue Zhi Kang Heart K Group Allied With Research InstituteExports Of Shijiazhuang No.2 Pharma Increases Meidakang Pharma Passed GMP CertificationShanghai Sine Pharma ExpandedBaiyunshan Secured Listing On Domestic Stock Exchange Managers Left Jiuyuan Genetic Engineering To Form Taishi BiotechNorth China Group Set Goals For 2000Xinbeijiang Pharma Flourishing Beijing Medical Trading Company Sustained Growth In 1999RegulationsGuidance For Healthcare System Reform In Urban Area ReleasedReform Of Drug Distribution SystemBattle between SETC and SDAMarket AnalysisAnalysis Of Major Chinese Biopharmaceutical MarketsAnalysis of Major Biopharmaceutical ProductsAntibiotics Market AnalysisNews BriefChinese Pharmaceutical Sector Grows At Double-Digit RateIncrease in Medical Expenditures Curbed in ChinaThirty Percent of Newborns In China Failed To Receive Hepatitis B Vaccination AIDS & Venereal Diseases Prevention& Treatment System To Be Set Up In ChinaDrug Research And Innovation Center Commenced OperationChina Received Japanese-Aided Cold Chain Equipment & VaccinesNew Findings On EpidemiologyOf Chronic Obstructive Lung Diseases In ChinaUtilization Of Healthcare Resources Needs To Be ImprovedBasic-Level Medical Service Network Set Up In Urban AreasVillage-Level Medical Institutions Diminished In NumberOver 60 Percent of Drug Applicants Were Single Entities in 1999Usage of Household Drugs In 20 Chinese Cities SurveyedChinese Pharmacopoeia 2000 PublishedEfficiency of Corporate-Funded Hospitals Dropped

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.